Literature DB >> 10350460

Mechanistic studies of the folding of human lysozyme and the origin of amyloidogenic behavior in its disease-related variants.

D Canet1, M Sunde, A M Last, A Miranker, A Spencer, C V Robinson, C M Dobson.   

Abstract

The unfolding and refolding properties of human lysozyme and two amyloidogenic variants (Ile56Thr and Asp67His) have been studied by stopped-flow fluorescence and hydrogen exchange pulse labeling coupled with mass spectrometry. The unfolding of each protein in 5.4 M guanidine hydrochloride (GuHCl) is well described as a two-state process, but the rates of unfolding of the Ile56Thr variant and the Asp67His variant in 5.4 M GuHCl are ca. 30 and 160 times greater, respectively, than that of the wild type. The refolding of all three proteins in 0.54 M GuHCl at pH 5.0 proceeds through persistent intermediates, revealed by multistep kinetics in fluorescence experiments and by the detection of well-defined populations in quenched-flow hydrogen exchange experiments. These findings are consistent with a predominant mechanism for refolding of human lysozyme in which one of the structural domains (the alpha-domain) is formed in two distinct steps and is followed by the folding of the other domain (the beta-domain) prior to the assembly of the two domains to form the native structure. The refolding kinetics of the Asp67His variant are closely similar to those of the wild-type protein, consistent with the location of this mutation in an outer loop of the beta-domain which gains native structure only toward the end of the refolding process. By contrast, the Ile56Thr mutation is located at the base of the beta-domain and is involved in the domain interface. The refolding of the alpha-domain is unaffected by this substitution, but the latter has the effect of dramatically slowing the folding of the beta-domain and the final assembly of the native structure. These studies suggest that the amyloidogenic nature of the lysozyme variants arises from a decrease in the stability of the native fold relative to partially folded intermediates. The origin of this instability is different in the two variants, being caused in one case primarily by a reduction in the folding rate and in the other by an increase in the unfolding rate. In both cases this results in a low population of soluble partially folded species that can aggregate in a slow and controlled manner to form amyloid fibrils.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10350460     DOI: 10.1021/bi983037t

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  43 in total

1.  High-sensitivity fluorescence anisotropy detection of protein-folding events: application to alpha-lactalbumin.

Authors:  D Canet; K Doering; C M Dobson; Y Dupont
Journal:  Biophys J       Date:  2001-04       Impact factor: 4.033

2.  Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy.

Authors:  M Bouchard; J Zurdo; E J Nettleton; C M Dobson; C V Robinson
Journal:  Protein Sci       Date:  2000-10       Impact factor: 6.725

3.  Ultrastructural organization of amyloid fibrils by atomic force microscopy.

Authors:  A K Chamberlain; C E MacPhee; J Zurdo; L A Morozova-Roche; H A Hill; C M Dobson; J J Davis
Journal:  Biophys J       Date:  2000-12       Impact factor: 4.033

4.  Protein engineering as a strategy to avoid formation of amyloid fibrils.

Authors:  V Villegas; J Zurdo; V V Filimonov; F X Avilés; C M Dobson; L Serrano
Journal:  Protein Sci       Date:  2000-09       Impact factor: 6.725

5.  Characterization of the oligomeric states of insulin in self-assembly and amyloid fibril formation by mass spectrometry.

Authors:  E J Nettleton; P Tito; M Sunde; M Bouchard; C M Dobson; C V Robinson
Journal:  Biophys J       Date:  2000-08       Impact factor: 4.033

6.  Characterization of the structure and dynamics of amyloidogenic variants of human lysozyme by NMR spectroscopy.

Authors:  A K Chamberlain; V Receveur; A Spencer; C Redfield; C M Dobson
Journal:  Protein Sci       Date:  2001-12       Impact factor: 6.725

7.  Simulations of human lysozyme: probing the conformations triggering amyloidosis.

Authors:  George Moraitakis; Julia M Goodfellow
Journal:  Biophys J       Date:  2003-04       Impact factor: 4.033

8.  Mutations in the B1 domain of protein G that delay the onset of amyloid fibril formation in vitro.

Authors:  Marina Ramírez-Alvarado; Melanie J Cocco; Lynne Regan
Journal:  Protein Sci       Date:  2003-03       Impact factor: 6.725

9.  A non-native alpha-helix is formed in the beta-sheet region of the molten globule state of canine milk lysozyme.

Authors:  Masahiro Watanabe; Yoshihiro Kobashigawa; Tomoyasu Aizawa; Makoto Demura; Katsutoshi Nitta
Journal:  Protein J       Date:  2004-07       Impact factor: 2.371

10.  A non-natural variant of human lysozyme (I59T) mimics the in vitro behaviour of the I56T variant that is responsible for a form of familial amyloidosis.

Authors:  Christine L Hagan; Russell J K Johnson; Anne Dhulesia; Mireille Dumoulin; Janice Dumont; Erwin De Genst; John Christodoulou; Carol V Robinson; Christopher M Dobson; Janet R Kumita
Journal:  Protein Eng Des Sel       Date:  2010-04-09       Impact factor: 1.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.